Cancel
Reenie McCarthy
Chief Executive Officer
@
Stealth BioTherapeutics
j59ug6.57gvwp53@2k0x2w3wd.04p
Sign up to see email
Known information
- Is a 20+ year veteran of the investment team of Morningside.
- Has extensive experience working with private nonclinical and clinical stage companies developing drugs across a broad spectrum of therapeutic areas.
About Stealth BioTherapeutics
Stealth BioTherapeutics develops therapies for mitochondrial dysfunction related to genetic diseases and aging, with a focus on elamipretide and SBT-272 in clinical studies.
Report inaccurate information
